Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response

BACKGROUND: HCV GT4 accounts for up to 20% of HCV infections worldwide. Simeprevir, given for 12 weeks as part of a 24- or 48-week combination regimen with PR is approved for the treatment of chronic HCV GT4 infection. Primary study objectives were assessment of efficacy and safety of simeprevir plu...

Descripción completa

Detalles Bibliográficos
Autores principales: Asselah, Tarik, Moreno, Christophe, Sarrazin, Christoph, Gschwantler, Michael, Foster, Graham R., Craxí, Antonio, Buggisch, Peter, Sanai, Faisal, Bicer, Ceyhun, Lenz, Oliver, Van Dooren, Gino, Nalpas, Catherine, Lonjon-Domanec, Isabelle, Schlag, Michael, Buti, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215882/
https://www.ncbi.nlm.nih.gov/pubmed/28056030
http://dx.doi.org/10.1371/journal.pone.0168713

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215882/
https://www.ncbi.nlm.nih.gov/pubmed/28056030
http://dx.doi.org/10.1371/journal.pone.0168713

Ejemplares similares